Lonnie Moulder (L) and Hua Mu
Xencor says goodbye to its former lead drug, selling all rights to Lonnie Moulder's new startup
More than three years after its lead program failed a Phase II study, Xencor is passing off the drug to an up-and-coming Hong Kong biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
